RBC Capital Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Sector Perform, After FDA CRL
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay downgraded BioMarin Pharmaceutical Inc. (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
